- Home
- Companies
- united kingdom
- oncology drug
Refine by
Industries served
Oncology Drug Suppliers In United Kingdom
5 companies found
based inNottingham, UNITED KINGDOM
Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based ...
Viewing cancer through the immune lens (immuno-oncology) has led to the most promising advancements in cancer treatment in recent history, nonetheless the full potential of the approach is as yet ...
based inCambridge, UNITED KINGDOM
CN Bio is a leading bioengineering company specialising in single and multi-organ microphysiological systems and innovative lab technologies. We aim to provide systems that generate clinically translatable data that can enhance the development of ...
Arranged in a multi-well format, the PhysioMimix™ MPS-LC12 plate has 12 independent ...
based inLondon, UNITED KINGDOM
Informa is a leading business intelligence, academic publishing, knowledge and events business, operating within the Knowledge and Information Economy. We serve commercial, professional and academic communities in many different sectors by helping ...
based inOxford, UNITED KINGDOM
Physiomics are a leading oncology consultancy using proprietary state of the art Virtual TumourTM technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help ...
Virtual Tumour™ is our advanced, predictive modelling simulation tool used worldwide by global pharmaceuticals to small biotech companies to support oncology ...
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody ...